Bolar's sustained release procainamide HCI
Shipments of the first generic version of Park-Davis' Procan SR approved by FDA are underway. Bolar estimates a 5-10% share of Parke-Davis' $60 mil. market for its generic. The product is available in 250 mg, 500 mg and 750 mg tabs, each in bottles of 100, 500, and 1,000. Price to whslrs. for the biggest selling item, 500 mg 100s, is $20.43. Bolar said it expects approval for a generic of Ciba's Ismelin (guanthidine monosulfate) in January
You may also be interested in...
A study with nearly 500 patients with vitamin D levels tested within a year before receiving COVID-19 tests found subjects deficient in the nutrient had 1.77 greater chance of testing positive. Researchers say RCTs are needed to determine if broad population interventions are necessary.
The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.
Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.